A Snip From the Annual Report June 2020, CGB'S Executive Director Sholom Feldman's Letter to Shareholders. Sholom Talks about The Australian Therapeutic Goods Administration's (TGA) interim decision made on 9th of September 2020 to reclassify low dose Cannabidiol (CBD) Products allowing them to be sold from behind the counter at Pharmacies without a prescription.
Sholom then says how this will benefit Cann Global through the sales of CannTabs "Cannabinoid Tablets" directly to Pharmacies. There is one small problem with this vision, CannTabs Tablets are a mixture of Cannabinoids (CBD) and Tetrahydrocannabinol (THC) which will not qualify them to be sold without a prescription from a Doctor; the TGA interim ruling is in regards to CBD products only.
From Sholoms letter to shareholders;
I have attached below an extract of and the Link to the TGA Interim decision, (Starts on Page 22)
This is from a Recent announcement from CannTab, which state their Tablets are a combination of THC and CBD
https://canntab.ca/
Extract of TGA Decision;
https://www.tga.gov.au/sites/default/files/notice-interim-decisions-proposed-amendments-poisons-standard-acms-and-joint-acms-accs-meetings-june-2020.pdf
Cheers
Finn
